Bristol Myers Squibb (BMY) gave investors a mixed picture for the year ahead: the drugmaker lifted its 2026 revenue forecast on the back of strong demand for its newer medicines, but it also cut its profit outlook after accounting for a hefty acquisition-related charge.
The company now expects 2026 revenue of $49.75 billion to $50.25 billion, up from its previous range of $49 billion to $50 billion. However, it trimmed its adjusted earnings per share (EPS) guidance to $6.35 to $6.55, down from the earlier $6.75 to $7.00. The roughly 40-cent reduction at the midpoint reflects a 58-cent charge tied to recent acquisitions.
Newer drugs drive the sales upgrade
The brighter sales picture comes from momentum in Bristol Myers's newer portfolio. In the third quarter, total revenue climbed 7% to $13.1 billion, with management pointing to strength in several key products:
- Breyanzi, a CAR-T cell therapy for certain blood cancers,
- Reblozyl, a treatment for anemia,
- Qvantig, an under-the-skin version of the blockbuster immunotherapy Opdivo.
These newer drugs are part of Bristol Myers's strategy to offset declining sales of older medicines, particularly the infused form of Opdivo, which faces competition from biosimilars and other alternatives. The company has been investing heavily in its pipeline and through acquisitions to build a more diversified portfolio.
The sales upgrade is a positive signal that the company's growth investments are paying off, even as the profit outlook takes a hit from deal-related costs.
What the acquisition charge means
The 58-cent charge is tied to acquisitions Bristol Myers has made to bolster its pipeline. Such charges are common when companies buy other businesses, as they include costs like amortization of intangible assets or one-time expenses related to the deal.
For investors, it's important to distinguish between the charge and the underlying business performance. Adjusted EPS excludes certain items, but the company chose to include this charge in its adjusted guidance, which is why the profit forecast dropped even though sales are expected to be higher.
This is a reminder that a company's reported profit can be affected by non-operating items, and that guidance changes can reflect accounting adjustments rather than a deterioration in the core business.
What it means for investors
For everyday investors, the key takeaway is that Bristol Myers is seeing stronger demand for its newer products, which is a good sign for future revenue growth. However, the lower profit forecast shows that acquisitions come with costs that can weigh on near-term earnings.
When a company raises its sales outlook but cuts its profit forecast, it often signals that growth is coming at a price. Investors should watch whether the sales momentum continues and whether the company can eventually convert that revenue growth into higher profits.
Bristol Myers's situation is not unique. Many drugmakers are facing patent expirations on older blockbusters and are using deals to refresh their pipelines. The success of those deals will determine whether the company can sustain its growth over the long term.
For now, the market will likely focus on the strength of the newer drugs and whether the company can manage its costs effectively. The raised sales guidance is a positive, but the cut to profit guidance is a caution flag.
As with any company, investors should consider the broader context. Bristol Myers operates in a competitive pharmaceutical landscape, and its ability to maintain momentum with new products will be crucial. The company's next earnings report will be closely watched for further updates on sales trends and any additional charges.
In the meantime, the mixed guidance highlights the balancing act that drugmakers face: investing in growth while managing the financial impact of those investments.
